Briacell Therapeutics Corp. Common Shares (BCTX) is a publicly traded Healthcare sector company. As of July 7, 2026, BCTX trades at $3.50 with a market cap of $28.36M and a P/E ratio of -0.06. BCTX moved +0.00% today. Year to date, BCTX is -53.89%; over the trailing twelve months it is -87.97%. Its 52-week range spans $2.60 to $190.50. Rallies surfaces BCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BriaCell Retains CRA, Kaleio to Drive US Market Access Ahead of Phase 3 Readout: BriaCell engaged Charles River Associates to evaluate US epidemiology, pricing and prescriber dynamics for Bria-IMT in metastatic breast cancer, and hired Kaleio for brand strategy and commercial-readiness solutions. These steps coincide with its pivotal Phase 3 trial and aim to advance market access planning pending successful outcomes.
| Metric | Value |
|---|---|
| Price | $3.50 |
| Market Cap | $28.36M |
| P/E Ratio | -0.06 |
| EPS | $-62.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $190.50 |
| 52-Week Low | $2.60 |
| Volume | 116.80K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.56M |
| Gross Margin | 0.00% |
BCTX analyst coverage data. Average price target: $0.00.